DICEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (9 8月 2023 @ 05:00):

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas...

Stats
本日の出来高	4.33M
平均出来高	1.75M
時価総額	2.27B
EPS	$0 ( 2024-03-14 )
次の収益日	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.91
ATR14	$0.513 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-09	Ra Capital Management, L.p.	Sell	786 407	Common Stock
2023-08-09	Ra Capital Management, L.p.	Sell	21 250	Stock Option (Right to Buy)
2023-08-09	Tetlow Sharon	Sell	49 841	Common Stock
2023-08-09	Tetlow Sharon	Sell	13 800	Stock Option (right to buy)
2023-08-09	Tetlow Sharon	Sell	21 250	Stock Option (right to buy)

INSIDER POWER
-56.66
Last 99 transactions
Buy: 13 025 781 \| Sell: 10 716 392

ボリューム相関

長: 0.25 (neutral)

短: 0.00 (neutral)

Signal:(77.583) Neutral

DICE Therapeutics, Inc. 相関

10 最も正の相関
MRNS	0.883
DGNU	0.879
ABCM	0.863
ABEO	0.86
SKYW	0.86
SINO	0.859
FSFG	0.858
CGNT	0.858
DFH	0.855
IRBT	0.851

10 最も負の相関
WYNN	-0.869
MCFT	-0.869
LIBY	-0.867
LSCC	-0.866
ASUR	-0.865
TGLS	-0.864
ULTA	-0.863
KYCH	-0.863
ARYD	-0.863
LAKE	-0.863

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

DICE Therapeutics, Inc. 相関 - 通貨/商品

-0.72
( moderate negative )

-0.74
( moderate negative )

0.36
( neutral )

-0.75
( moderate negative )

-0.13
( neutral )

0.68
( moderate )

DICE Therapeutics, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.07

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.07

FY	2021
収益:	$1.13M
総利益:	$1.13M (100.00 %)
EPS:	$-2.11

FY	2020
収益:	$863 000
総利益:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.